AZ’s COVID-19 jab sales top $1.2bn, but come at a lossAstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in Share XAZ’s COVID-19 jab sales top $1.2bn, but come at a losshttps://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Pfizer says COVID-19 jab could rake in $26bn this yearPfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it Share XPfizer says COVID-19 jab could rake in $26bn this yearhttps://pharmaphorum.com/news/pfizer-says-covid-19-jab-could-rake-in-26bn-this-year/
23andMe goes public using Richard Branson’s blank cheque companyDNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Share X23andMe goes public using Richard Branson’s blank cheque companyhttps://pharmaphorum.com/news/23andme-goes-public-using-richard-bransons-blank-cheque-company/
AZ closes $400 million Atacand sale to Germany’s CheplapharmAstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as Share XAZ closes $400 million Atacand sale to Germany’s Cheplapharmhttps://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/
BMS/Celgene merger payout evaporates as CVR deadline passesFormer Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three Share XBMS/Celgene merger payout evaporates as CVR deadline passeshttps://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
